G

Grown Rogue International Inc
CNSX:GRIN

Watchlist Manager
Grown Rogue International Inc
CNSX:GRIN
Watchlist
Price: 0.99 CAD 4.21% Market Closed
Market Cap: 220.1m CAD
Have any thoughts about
Grown Rogue International Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one GRIN stock under the Base Case scenario is 0.26 CAD. Compared to the current market price of 0.99 CAD, Grown Rogue International Inc is Overvalued by 73%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GRIN Relative Value
Base Case
0.26 CAD
Overvaluation 73%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

7.3
P/S
P/S
Price to Sales
7.3
vs History
25
vs Industry
30
Median 3Y
1.6
Median 5Y
4.1
Industry
2.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
10
Median 3Y
-8.3
Median 5Y
-8.3
Industry
21.8
More Details
28.5
P/OCF
P/OCF
Price to OCF
28.5
vs History
12
vs Industry
24
Median 3Y
9.4
Median 5Y
7
Industry
16.1
More Details
56.8
P/FCFE
P/FCFE
Price to FCFE
56.8
vs History
7
vs Industry
27
Median 3Y
7.3
Median 5Y
-6.4
Industry
23.8
More Details
14.8
P/B
P/B
Price to Book Value
14.8
vs History
9
vs Industry
11
Median 3Y
4.1
Median 5Y
3.1
Industry
2.1
More Details
7.1
EV/S
EV/S
Enterprise Value to Sales
7.1
vs History
25
vs Industry
29
Median 3Y
1.5
Median 5Y
4.3
Industry
2.7
More Details
13.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.2
vs History
47
vs Industry
28
Median 3Y
3.5
Median 5Y
11.1
Industry
5.2
More Details
43.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
43.7
vs History
12
vs Industry
21
Median 3Y
19.9
Median 5Y
8.5
Industry
13.5
More Details
54.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
54.4
vs History
11
vs Industry
22
Median 3Y
13.2
Median 5Y
-3.9
Industry
16.8
More Details
27.7
EV/OCF
EV/OCF
Enterprise Value to OCF
27.7
vs History
12
vs Industry
25
Median 3Y
9.3
Median 5Y
7.4
Industry
15.2
More Details
36
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
36
vs History
12
vs Industry
19
Median 3Y
13.9
Median 5Y
-5.2
Industry
19.3
More Details
5.1
EV/IC
EV/IC
Enterprise Value to IC
5.1
vs History
47
vs Industry
28
Median 3Y
2.1
Median 5Y
4.1
Industry
1.9
More Details

Multiples Across Competitors

GRIN Competitors Multiples
Grown Rogue International Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Grown Rogue International Inc
CNSX:GRIN
220.1m CAD 7.3 -11 43.7 54.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/E Multiple
Earnings Growth P/E to Growth
CA
G
Grown Rogue International Inc
CNSX:GRIN
Average P/E: 31.6
Negative Multiple: -11 		N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
G
Grown Rogue International Inc
CNSX:GRIN
Average EV/EBITDA: 417.6
43.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
G
Grown Rogue International Inc
CNSX:GRIN
Average EV/EBIT: 1 815.2
54.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Summary
GRIN intrinsic value, competitors valuation, and company profile.
DCF Valuation
GRIN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GRIN stock valuation using valuation multiples.
Wall Street Estimates
GRIN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GRIN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.